Manuel Serrano Rios
Overview
Explore the profile of Manuel Serrano Rios including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wheeler E, Leong A, Liu C, Hivert M, Strawbridge R, Podmore C, et al.
PLoS Med
. 2017 Sep;
14(9):e1002383.
PMID: 28898252
Background: Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic...
2.
Larrad M, Anchuelo A, Fernandez Perez C, Perez Barba M, Lazcano Redondo Y, Serrano Rios M
PLoS One
. 2016 May;
11(5):e0153976.
PMID: 27166797
Objectives: Our aim was to investigate if genetic variations in the visfatin gene (SNPs rs7789066/ rs11977021/rs4730153) could modify the cardiovascular-risk (CV-risk) despite the metabolic phenotype (obesity and glucose tolerance). In...
3.
Serrano Rios M
An R Acad Nac Med (Madr)
. 2013 Jan;
128(4):627-47.
PMID: 23350308
No abstract available.
4.
Kilpelainen T, Qi L, Brage S, Sharp S, Sonestedt E, Demerath E, et al.
PLoS Med
. 2011 Nov;
8(11):e1001116.
PMID: 22069379
Background: The FTO gene harbors the strongest known susceptibility locus for obesity. While many individual studies have suggested that physical activity (PA) may attenuate the effect of FTO on obesity...
5.
Rodriguez Bernardino A, Garcia Polavieja P, Reviriego Fernandez J, Serrano Rios M
Endocrinol Nutr
. 2010 Feb;
57(2):60-70.
PMID: 20153706
Objective: To determine the prevalence of metabolic syndrome, the degree of consistency among World Health Organization (WHO), The Third Report National Cholesterol Education Program (NCEP-ATP III) and the International Diabetes...
6.
Seclen S, Villena A, Larrad M, Gamarra D, Herrera B, Fernandez Perez C, et al.
Metab Syndr Relat Disord
. 2008 Mar;
4(1):1-6.
PMID: 18370764
Background: The metabolic syndrome (MS) has been shown to predict mortality due to cardiovascular disease. Currently, no population-based data on the prevalence of the MS is available in Peru. This...
7.
Palma Gamiz J, Conget Donlo I, Bertomeu Gonzalez V, Ascaso Gimilio J, Gonzalez Juanatey J, Alegria Ezquerra E, et al.
Med Clin (Barc)
. 2007 Mar;
128(11):407-13.
PMID: 17394855
Background And Objective: To assess the prevalence of metabolic syndrome (MS) and cardiovascular risk factors in patients with established cardiovascular disease (CVD). Patients And Method: Epidemiologic, cross-sectional, multicentre and national...
8.
Zimmet P, Alberti K, Serrano Rios M
Rev Esp Cardiol
. 2005 Dec;
58(12):1371-6.
PMID: 16371194
No abstract available.
9.
Franks P, Luan J, Barroso I, Brage S, Sanchez J, Ekelund U, et al.
Diabetes
. 2005 Aug;
54(9):2795-801.
PMID: 16123371
Endothelium-derived nitric oxide (NO) facilitates skeletal muscle glucose uptake. Energy expenditure induces the endothelial NO synthase (eNOS) gene, providing a mechanism for insulin-independent glucose disposal. The object was to test...
10.